AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RECCE PHARMACEUTICALS LTD

0.265

-0.025-8.62%

Volume:147.06K

Turnover:40.74K

Market Cap:80.96M

PE:-5.13

High:0.285

Open:0.285

Low:0.265

Close:0.290

52wk High:0.730

52wk Low:0.265

Shares:305.52M

Float Shares:168.89M

Volume Ratio:1.01

T/O Rate:0.09%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.052

EPS(LYR):-0.052

ROE:-1277.62%

ROA:-82.75%

PB:-4.84

PE(LYR):-5.13

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Recce Pharmaceuticals Shareholder Proposes Board Changes, Nominates Four Directors

MT Newswires Live

Recce Pharmaceuticals Gets Ethics Approval for New Study Arm in Phase 3 Trial of Diabetic Foot Infection Treatment

MT Newswires Live

Recce Pharmaceuticals in Position to Benefit from US ASPR Medical Countermeasures Strategy

MT Newswires Live

Recce Pharmaceuticals Ltd - Developing New Class of Synthetic Anti- Infectives Designed to Address Antibiotic-Resistant Superbugs

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://nz.tigermarketb.com/stock/RCE.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"RCE.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RCE.AU\",,,,,undefined,":{"symbol":"RCE.AU","market":"AU","secType":"STK","nameCN":"RECCE PHARMACEUTICALS LTD","latestPrice":0.265,"timestamp":1791868320000,"preClose":0.29,"halted":0,"volume":147062,"delay":0,"changeRate":-0.08620689655172403,"nameEN":"RECCE PHARMACEUTICALS LTD","floatShares":168893037,"shares":305520100,"eps":-0.0517,"marketStatus":"Not Yet Opened","change":-0.025,"latestTime":"10-13 16:12:00 AEDT","open":0.285,"high":0.285,"low":0.265,"amount":40736,"amplitude":0.068966,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.0517,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1791932400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.29,"openAndCloseTimeList":[[1791846000000,1791867600000]],"volumeRatio":1.0132870676360852,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"RCE.AU","preClose":0.265,"auctionPrice":0.27,"auctionVolume":703,"auctionTime":1791921608700,"referenceTime":1791887404086,"auction":1,"marketStatus":"盘前竞价","timestamp":1791921608700}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"RCE.AU\",,,,,undefined,":{"symbol":"RCE.AU","floatShares":168893037,"roa":"-82.75%","roe":"-1277.62%","lyrEps":-0.0517,"volumeRatio":1.0132870676360852,"shares":305520100,"dividePrice":0,"high":0.285,"amplitude":0.068966,"preClose":0.29,"low":0.265,"week52Low":0.265,"pbRate":"-4.84","psRate":"8.55","week52High":0.73,"institutionHeld":0,"latestPrice":0.265,"eps":-0.0517,"divideRate":0,"volume":147062,"delay":0,"ttmEps":-0.0517,"open":0.285,"prevYearClose":0.65,"prevWeekClose":0.295,"prevMonthClose":0.315,"prevQuarterClose":0.315,"fiveDayClose":0.315,"twentyDayClose":0.32,"sixtyDayClose":0.37,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RCE.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2025-04-15","symbol":"RCE.AU","defaultRemindTime":1744675200000,"type":"split","dateTimestamp":1744639200000,"forFactor":990476,"toFactor":1000000,"ratio":0.990476}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RCE.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RCE.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2671216240","title":"Recce Pharmaceuticals Shareholder Proposes Board Changes, Nominates Four Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2671216240","media":"MT Newswires Live","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671216240?lang=en_us&edition=fundamental","pubTime":"2026-09-30 06:04","pubTimestamp":1790719484,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals  substantial holder Gavin William Brown has proposed two shareholder resolutions, including a constitutional amendment to allow non-binding recommendations to directors and the establishment of an independent advisory council to review the company's clinical, commercial, and corporate strategy, according to an Australian bourse filing on Tuesday after market hours.Brown has also nominated four candidates, Paul MacLeman, Jurgen Michaelis, Amos Meltzer, and Diana Forsyth, for election as directors at the annual general meeting, per the filing.The company is assessing the validity of the proposals and nominations, with any valid resolutions to be presented to shareholders alongside the board's recommendations, the filing added.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7096","RCE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660419483","title":"Recce Pharmaceuticals Gets Ethics Approval for New Study Arm in Phase 3 Trial of Diabetic Foot Infection Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2660419483","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660419483?lang=en_us&edition=fundamental","pubTime":"2026-08-19 11:10","pubTimestamp":1787109038,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals  gained Human Research Ethics Committee approval for an amendment to its phase 3 clinical trial of Recce 327 topical gel for the potential treatment of diabetic foot infections in Australia, according to a Wednesday filing with the Australian bourse.The amendment adds a new randomized, active-controlled, non-inferiority study arm enrolling 208 participants, which will allow the company to generate comparative clinical data for the gel against antibiotic treatment options.The updated protocol also introduces wound imaging, which adds a further layer of objective assessment of the infection to strengthen the Recce 327 data package for global regulatory submissions, the company said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RCE.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655984624","title":"Recce Pharmaceuticals in Position to Benefit from US ASPR Medical Countermeasures Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2655984624","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655984624?lang=en_us&edition=fundamental","pubTime":"2026-07-30 09:58","pubTimestamp":1785376729,"startTime":"0","endTime":"0","summary":"Recce Pharmaceuticals  said it was well positioned to benefit from the US Administration for Strategic Preparedness and Response's  new five-year medical countermeasures funding strategy, which ranked antimicrobial resistance the second-highest funding priority in the plan, with $4.46 billion earmarked for broad-spectrum antimicrobials, according to a Thursday Australian bourse filing.The funding aims to help antimicrobial candidates through each development stage, from preclinical research through to clinical trials and regulatory approval.The firm's RECCE 327 treatment candidate has shown activity against a number of pathogen classes under its existing US Department of War programs, the filing noted.Its shares rose 1% in recent trading on Thursday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ASPR","BK4009","BK7096","RCE.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655479843","title":"Recce Pharmaceuticals Ltd - Developing New Class of Synthetic Anti- Infectives Designed to Address Antibiotic-Resistant Superbugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2655479843","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655479843?lang=en_us&edition=fundamental","pubTime":"2026-07-30 08:38","pubTimestamp":1785371927,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nTUE1ZTYHT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","RCE.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":8,"pageCount":1,"totalSize":30,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/RCE.AU\",params:#limit:6,delay:true,,,undefined,":[]}}